Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aurora Cannabis Announces First Quarter 2020 Results & Corporate Action Plan
NYSE | TSX: ACB
Reports Industry Leading Gross Profit of $53.7 Million and 58% Cannabis Gross Margin
Delivers Best-in-Class Indoor Cash Cost to Produce of $0.85 per gram
Announces Plan to Settle March 2020 5.0% Convertible Debentures
Revises Capital Expenditure Plan to Align with Long-Term Market Growth
Generates Total Revenue of $75.6 Million Including Medical and Consumer Cannabis Net Revenue of $60.5 Million, and Wholesale Cannabis Net Revenues of $10.3 Million
(Reuters) - Canopy Growth Corp (WEED.TO) reported a bigger quarterly loss on Thursday, as the Canadian pot producer was hit by restructuring and inventory charges as part of its portfolio review.
The Ontario-based company reported a wider net loss of C$374.6 million ($283.12 million), in the second quarter ended Sept. 30, from C$330.6 million, a year earlier.
On per share basis, the company reported a loss of C$1.08.
Net revenue rose to C$76.6 million from C$23.3 million.
"California's attorney general said he thinks the federal government is "not too far away” from catching up to states on marijuana policy."
from Marijuana Moment
Brilliant, Canopy... about time...
I know people who suffer with this...
some of my family in Scandinavia are already using their light boxes because they suffer from this SAD, this winter depression...
Khiron Receives Approval to Sell Aceso™ Hemp CBD Brand in Colombia
First Hemp CBD brand to enter Latin American market under Dixie Brands joint venture
Builds on proven Aceso brand acceptance across US consumer market
Product line includes indication-specific (heat and cool), hemp-derived CBD balms
Approval secured from INVIMA for commercialization in Colombia of initial Aceso products, Alfa Balm (heat) and Sigma Balm (cool)
Introduction to Colombian market in Q4 2019 with expansion to Chile and Uruguay in 2020
https://investors.khiron.ca/press-releases/detail/127/khiron-receives-approval-to-sell-aceso-hemp-cbd-brand-in
Organigram is pleased to announce that the company was celebrated for its world-class products at the sixth annual Canadian Cannabis Awards Gala in Toronto on November 8th!
Organigram was awarded top product award in the High THC Bottled Oil category for Rossignol, a sativa-dominant edible oil available to registered patients.
Organigram was also recognized in the following categories:
Brand of the Year, first runner up: The Edison Cannabis Co.
Top CBD Oil, first runner up: Organigram Shubie
Top Balanced Oil, first runner up: Organigram Utopia
Top High THC Bottled Oil, first runner up: Organigram Banook
Top Hybrid Flower, first runner up: Edison Cannabis Co. El Dorado
Top Hybrid Pre-Roll, first runner up: Edison Cannabis Co. City Lights Pre-Roll
Top Sativa Dominant Pre-Roll, first runner up: Trailblazer Flash Stix
Employer of the Year, finalist
Epidyolex and Sativex are manufactured in the UK by Cambridge-based GW Pharma.
Chris Tovey, GW’s Chief Operating Officer, said: ‘This is a momentous occasion for UK patients and families who have waited for so many years for rigorously tested, evidenced and regulatory approved cannabis-based medicines to be reimbursed by the NHS.
‘This is proof that cannabis-based medicines can successfully go through extensive randomised placebo-controlled trials and a rigorous NICE evaluation process to reach patients.
‘I am hugely proud of the entire GW team for achieving this milestone in the country where the company was founded and where both of these medicines were developed and are manufactured.’
https://www.dailymail.co.uk/health/article-7671119/Cannabis-drugs-epilepsy-multiple-sclerosis-approved-NHS-use.html
Cannabis on the UK's NHS: Marijuana-based drugs for epilepsy and multiple sclerosis are approved for use
Children suffering with life-threatening forms of epilepsy can now get Epidyolex
Multiple sclerosis (MS) patients will be offered cannabis-based Savitex spray
The two cannabis-based medications have been approved for use in the NHS
https://www.dailymail.co.uk/health/article-7671119/Cannabis-drugs-epilepsy-multiple-sclerosis-approved-NHS-use.html
Good news coming from Europe: Cannabis on the UK's NHS: Marijuana-based drugs for epilepsy and multiple sclerosis are approved for use
Thousands of patients will get cannabis-based medicines on the NHS after two drugs were approved for use.
https://www.dailymail.co.uk/health/article-7671119/Cannabis-drugs-epilepsy-multiple-sclerosis-approved-NHS-use.html
And over in Europe: Cannabis on the NHS: Marijuana-based drugs for epilepsy and multiple sclerosis are approved for use
Thousands of patients will get cannabis-based medicines on the NHS after two drugs were approved for use.
https://www.dailymail.co.uk/health/article-7671119/Cannabis-drugs-epilepsy-multiple-sclerosis-approved-NHS-use.html
In the UK: Cannabis on the NHS: Marijuana-based drugs for epilepsy and multiple sclerosis are approved for use
Thousands of patients will get cannabis-based medicines on the NHS after two drugs were approved for use.
https://www.dailymail.co.uk/health/article-7671119/Cannabis-drugs-epilepsy-multiple-sclerosis-approved-NHS-use.html
Cannabis on the NHS: Marijuana-based drugs for epilepsy and multiple sclerosis are approved for use
Thousands of patients will get cannabis-based medicines on the NHS after two drugs were approved for use.
https://www.dailymail.co.uk/health/article-7671119/Cannabis-drugs-epilepsy-multiple-sclerosis-approved-NHS-use.html
Excellent DD, Rowdy2, thanks.
does that mean my tenants are about to vacate...?
mind you, I cannot complain.... last month I made more in rent than I made in one year's salary in my former corporate career...
and soon we are back to the races...
thanks, Doubleeagle, you have constantly given sound advise on this board...
Khiron Enters First Latin American Cannabis Lines of Research Targeting U.S. $44 Billion Dermatological Drug Market
Clinical research partnership with Centro Dermatológico Federico Lleras Acosta (CDFLLA), focuses on effectiveness of medical cannabis for dermatological conditions defined in three main lines of research:
Melanoma, Keratinocytes and Mycobacterial growth.
Lines of research presented November 2, 2019 at II TeraCILAD dermatological conference with more than 1,000 LATAM dermatologists in attendance.
Research initiated by Khiron and CDFLLA anticipated to begin in Q1 2020, representing first of its kind in Latin America
Global dermatological (prescription) drug market valued at $38.4bn in 2017, rising to $44.1bn in 2018 (Source: GMR Data).
https://investors.khiron.ca/press-releases/detail/126/khiron-enters-first-latin-american-cannabis-lines-of
Is Warren onto this...?
wow it is huge... just huge... what a grow. Thanks, Wsstocks.
“Data from several countries reveal that medical cannabis have benefited several thousands of patients,” said Dr Arun Bhaskar, president of the British Pain Society. “There are more than eight million people with disabling chronic pain in the UK and medical cannabis is still out of reach for them.
https://www.theguardian.com/society/2019/nov/03/medical-cannabis-uk-clinical-trial-patients-nhs
Medical cannabis trial will target 20,000 UK patients
Project backed by Royal College of Psychiatrists aims to be largest on drug’s use in Europe
Up to 20,000 patients in the UK are to be given medical cannabis over a two-year period in an initiative that aims to create the largest body of evidence on the drug in Europe.
The move, to be unveiled on Thursday, is backed by one of the UK’s leading medical bodies and it is hoped it will persuade the NHS to prescribe the drug for a range of conditions.
Although medical cannabis was legalised in the UK a year ago, it remains unobtainable for many patients, according to campaigners.
“Medical cannabis is still out of reach for far too many,” said Professor David Nutt from the independent scientific body Drug Science, the organisation behind the launch of Project Twenty21, which will see 20,000 patients supplied with subsidised cannabis products by the end of 2021.
https://www.theguardian.com/society/2019/nov/03/medical-cannabis-uk-clinical-trial-patients-nhs
Medical cannabis trial will target 20,000 UK patients
Project backed by Royal College of Psychiatrists aims to be largest on drug’s use in Europe
Up to 20,000 patients in the UK are to be given medical cannabis over a two-year period in an initiative that aims to create the largest body of evidence on the drug in Europe.
The move, to be unveiled on Thursday, is backed by one of the UK’s leading medical bodies and it is hoped it will persuade the NHS to prescribe the drug for a range of conditions.
Although medical cannabis was legalised in the UK a year ago, it remains unobtainable for many patients, according to campaigners.
“Medical cannabis is still out of reach for far too many,” said Professor David Nutt from the independent scientific body Drug Science, the organisation behind the launch of Project Twenty21, which will see 20,000 patients supplied with subsidised cannabis products by the end of 2021.
https://www.theguardian.com/society/2019/nov/03/medical-cannabis-uk-clinical-trial-patients-nhs
Medical cannabis trial will target 20,000 UK patients
Project backed by Royal College of Psychiatrists aims to be largest on drug’s use in Europe
Up to 20,000 patients in the UK are to be given medical cannabis over a two-year period in an initiative that aims to create the largest body of evidence on the drug in Europe.
The move, to be unveiled on Thursday, is backed by one of the UK’s leading medical bodies and it is hoped it will persuade the NHS to prescribe the drug for a range of conditions.
Although medical cannabis was legalised in the UK a year ago, it remains unobtainable for many patients, according to campaigners.
“Medical cannabis is still out of reach for far too many,” said Professor David Nutt from the independent scientific body Drug Science, the organisation behind the launch of Project Twenty21, which will see 20,000 patients supplied with subsidised cannabis products by the end of 2021.
https://www.theguardian.com/society/2019/nov/03/medical-cannabis-uk-clinical-trial-patients-nhs
agree with you two guys... yeah it is fun, and education, to watch this unfold... it is only a baby industry...
thanks...
"You should see the Oct sales numbers from HC "... please, where do you see these figures.....
I'm intrigued and love it...
I have a very small opening position here, as I just did not dig, or understand, or feel a winning streak in this deal... because the politicians were involved...
The mettrum and bedrocan deals were winners, just simple commerce, and the numbers looked so lovely,
sold all me canopy and bought mettrum... what a lovely deal... my celebrations really damaged me liver.... lol
Now, I am beginning to turn and warm to this Acreage move .... I'm thinking the politicians have now lined their pockets, and so the senate will soonish pass this SAFE law...
then, as twister would say, the dog is off the leash and hopefully we will all be off to the races...
Organigram is pleased to announce that the Company was recognized at the Excellence in Manufacturing Consortium (“EMC”) Awards of Excellence ceremony in Toronto on October 9.
Organigram was honoured with an Outstanding Member Contribution Award for delivering exemplary support to the EMC over the course of the Company’s membership.
The award, accepted by Organigram Senior Vice President of Operational Services, Jeff Purcell, recognizes organizations which demonstrate outstanding achievement in manufacturing.
“Producing high-quality cannabis in a state-of-the-art indoor environment, Organigram operates in an interesting cross-section of horticulture, consumer packaged goods and manufacturing,” Purcell said. “We are very proud to accept this award and support EMC, a group that sets the standard for manufacturing excellence in Canada.”
Thanks, Funman. I appreciate the way you post the link and the story, because where I am some sites are blocked.
Looking forward to Aphria running this week.
hey Funman you are brilliant at posting lots of information on so many boards, where I am invested....
thanks man, really appreciate it....
the world needs more selfless guys like you to help us all track through the investment worlds....
spot on Rowdy2.
Sanders unveils plan to legalize marijuana, invest tax revenue in minority businesses
https://edition.cnn.com/2019/10/24/politics/bernie-sanders-marijuana-justice-plan/index.html
Sanders unveils plan to legalize marijuana, invest tax revenue in minority businesses
https://edition.cnn.com/2019/10/24/politics/bernie-sanders-marijuana-justice-plan/index.html
you fellas love to party.... LOL...
Retail sales in Canada are encouraging....
In April they sold 74k, and that went up to 127K in August.
Each month (April to August) shows increasing sales .....
and this industry is only in its infancy ......
Canada April: 74,584 May: 85,806 June: 91,460 July: 107,362 Aug: 127,381
Thanks to Hunch who has posted this on other boards
https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=2010000801&pickMembers%5b0%5d=2.30&pickMembers%5b1%5d=3.1
Good work, Hunch.
These retail sales are encouraging....
In April they sold 74k, and that went up to 127K in August.
Each month (April to August) shows increasing sales .....
and this industry is only in its infancy ......
Canada April: 74,584 May: 85,806 June: 91,460 July: 107,362 Aug: 127,381
Many thanks, Hunch...
These retail sales are encouraging....
In April they sold 74k, and that went up to 127K in August......
Each month (April to August) shows increasing sales .....
and this industry is only in its infancy ......
Canada April: 74,584 May: 85,806 June: 91,460 July: 107,362 Aug: 127,381
These retail sales are encouraging.... In April they sold 74k, and that went up to 127K in August...... Each month (April to August) shows increasing sales ..... and this industry is only in its infancy ...... Canada April: 74,584 May: 85,806 June: 91,460 July: 107,362 Aug: 127,381
thanks, Hunch.
This is good news.... and this sector needs good news, and not hypers or groomers...
So for all of Canada: April was 74k and it went up to 127k in august...
Canada 74,584B 85,806A 91,460A 107,362A 127,381
And this is only a baby industry ... still in its infancy....
good news Hunch... thanks... big run in nov, eh...?
can't believe last month's rent... knocked me out....
the East here is slow... very slow... don't believe the hype ... around here you get life for a kilo... in Canada they give you a couple of dollars for it...